‘’ On January 6, 2023, the U.S. Food and Drug Administration approved the new drug Leqembi (also known as lecanemab) for treatment of early Alzheimer’s disease. Here’s what people in Canada might want to know about it.’’ 

To read the full article, click here: Your questions, answered: What should Canadians know about lecanemab’s U.S. FDA approval? | Alzheimer Society of Canada